ClinicaliQ Trial Snapshot
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) — Active Not Recruiting • Phase III • NCT04586231.
- Belzutifan plus lenvatinib compared to cabozantinib for treating advanced kidney cancer after prior treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival. Conditions: Carcinoma, Renal Cell Interventions: Belzutifan, Lenvatinib, Cabozantinib Lead Sponsor: Merck Sharp & Dohme LLC Planned Enrollment: 747 participants